Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Codexis expands advisory board for RNA synthesis platform

EditorEmilio Ghigini
Published 2024-02-20, 08:12 a/m
Updated 2024-02-20, 08:12 a/m
© Reuters.

REDWOOD CITY, Calif. - Codexis , Inc. (NASDAQ: NASDAQ:CDXS), a prominent enzyme engineering firm, announced today the addition of Masad Damha, PhD, and Jim Lalonde, PhD, to its Strategic Advisory Board (SAB). These appointments aim to bolster the company's strategic direction and innovation in RNA-based therapeutic manufacturing with the ECO Synthesis™ platform.

The SAB, which includes John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals, will now benefit from Dr. Damha's expertise in RNA targeting and gene editing, as well as Dr. Lalonde's extensive background in enzyme engineering. Stefan Lutz, PhD, Senior Vice President of Research at Codexis, expressed confidence that the new board composition will enhance the company's progress towards technical milestones and facilitate early access customer testing slated for the latter half of 2024.

Dr. Damha, a Distinguished James McGill Professor at McGill University and co-founder of Anagenis, Inc., has contributed significantly to new therapeutic drugs and authored over 200 publications. His FANA technology is applied in various research and industry settings to develop modified oligonucleotides for targeting diseases.

Dr. Lalonde, a former Codexis Senior Vice President of Research and Development, has overseen the development of numerous enzymes for diverse applications. He currently consults for biotechnology startups and holds leadership positions in several scientific advisory boards.

The ECO Synthesis™ platform is being developed to address scalability and cost challenges in RNAi therapeutic production, which is expected to outpace current capabilities by the decade's end. Codexis achieved gram-scale synthesis in December 2023, demonstrating the potential of its enzymatic route for commercial-scale RNAi therapeutic manufacture.

3rd party Ad. Not an offer or recommendation by See disclosure here or remove ads .

Codexis specializes in creating high-performance enzymes and proteins through its proprietary CodeEvolver® technology platform, tackling challenges in pharmaceuticals manufacturing and nucleic acid synthesis. The company's ECO Synthesis™ platform represents a strategic move to capture market share in the burgeoning field of RNAi therapeutics.

The information for this article is based on a press release statement from Codexis, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.